Prof. Gregory Poland, MD, is Director of the Vaccine Research Group at the Mayo Clinic and Foundation, Rochester, MN, US.
Prof. Poland received his medical degree from the Southern Illinois University School of Medicine in Springfield, IL, US, and completed his residency and advanced postgraduate work at the University of Minnesota and Abbott Northwestern Hospital, Minneapolis, MN, US.
Prof. Poland’s research seeks to understand the genetic drivers of viral vaccine response and the application of systems biology approaches to the generation of immunity, as well as the development of novel vaccines that are important in public health. His research group has developed the field of viral vaccine immunogenetics, the immune response network theory, and the fields of vaccinomics and adversomics.
Prof. Poland holds the academic rank of Professor of Medicine and Infectious Diseases and Molecular Pharmacology and Experimental Therapeutics. He also serves as President of the Edward Jenner Vaccine Society and is Editor-in-Chief of the journal Vaccine. Prof. Poland has chaired or been a member of every US federal committee involved in vaccine decision-making, including the National Vaccine Advisory Committee (NVAC), the Vaccines and Related Biological Products Advisory Committee (VRBAC) and the Advisory Committee on Immunization Practices (ACIP). Prof. Poland advocated for and successfully persuaded the United States Centers for Disease Control and Prevention (CDC) to recommend annual influenza vaccination for all Americans aged 6 months and older, and was the initial and primary advocate for requiring influenza immunization for all healthcare providers.
Prof. Poland has published over 500 professional papers, book chapters and editorials. He is actively and regularly sought after by scientific and lay print, and TV and radio media for his views on vaccine policy. Prof. Poland is a popular conference and seminar speaker on the topics of vaccines, scientific literacy, vaccine hesitancy, scientific writing and publication, and biodefence.
EM-60501 - Date of preparation: April 2021